COST-EFFECTIVENESS ANALYSIS OF REMDESIVIR AND FAVIPIRAVIR THERAPY FOR THE TREATMENT OF COVID-19 IN ADULT PATIENTS AT THE HAJJ REGIONAL GENERAL HOSPITAL, EAST JAVA PROVINCE
Abstract
Cases of Coronavirus Disease 2019 or COVID-19 from year to year show a tendency to increase spread worldwide, including Indonesia. COVID-19 is an infectious disease caused by a virus so redeliver and Favipiravir antiviral therapy is needed. This study compared the cost-effectiveness analysis of the drugs Ravipiravir and Remdesivir in COVID-19 disease at Haji Hospital Surabaya. This study compares observationally between 2 (two) alternatives using a hospital perspective and data collection carried out retrospectively in the period April 2021 to October 2021. The Cost Effectiveness Analysis method used is the Cost-Effectiveness Ratio (ACER). The results of the data obtained from the ACER cost-effectiveness analysis method in the Favipiravir group are Rp. 2,820,601.63 per day for length of stay and Rp. 6,485,071.79 per day for COVID-19-free time. While in the Remdesivir group Rp. 3,311,510.74 per day for the length of stay and Rp. 8,329,527.98 per day for COVID-19-free time. Meanwhile, the ICER analysis method is Rp. 6,195,280.50 per day for the length of hospitalization and Rp. 34,802,899 per day for COVID-19-free time. This study concludes that Favipiravir is more cost-effective than Remdesivir.
Downloads
References
Kementerian Kesehatan Republik Indonesia. Situasi Terkini Perkembangan COVID-19, 2021. Kementerian Kesehatan ; 2021.
Rusdi MS. Farmakologi pada Corona Virus Disease atau COVID-19. Lumbung Farmasi Ilmu Kefarmasian. 2021;(103):54–61.
Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan H, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. Penyakit Dalam Indonesia. 2020;7(1):45.
Erlina Burhan, Agus Dwi Susanto, Sally A Nasution, Eka Ginanjar, Ceva Wicaksono Pitoyo, Adityo Susilo, Isman Firdaus, Anwar Santoso, Dafsah Arifa Juzar, Syafri Kamsul Arif, Navy G.H Lolong Wulung, Triya Damayanti, Wiwien Heru Wiyono, Prasenohadi, Afiatin, TC-19 I. Protokol Tatalaksana Covid-19. 2020.
Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020. Pedoman Tatalaksana COVID-19. 2020. 36–37 p.
Oksuz E, Malhan S, Gonen MS, et al. Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey. 2021;38(9):4935–48.
Al-Ardhi FM, Novotny L, Alhunayan A, Al-Tannak NF et al. Comparison of remdesivir and favipiravir Covid-19 agents RNA constituents. 2022;166(1):12–20.
Bootman JL, Townsend RJ, McGhan WF et al. Introduction to Pharmacoeconomics. In: Bootman JL, Townsend RJ, McGhan WF, editors. Principles of Pharmacoeconomics. 3rd. Cincinnati: Harvey Whitney Books Company; 2005. p. 1-10.
De Queljoe D, Lorensia A, Widharta L, Widjaja S et al. Cost-Effectiveness Analysis of Pharmacotherapy for Hematemesis-Melena Treatment in Hospitalized Patients with Hepatic Cirrhosis. Indonesia Biomed J. 2013;5(1):43.
Amelia, L., et al., Studi Cost-Consequences Analysis antara Salbutamol dengan Aminofilin untuk Pengobatan Serangan Asma, KELUWIH: Jurnal Kesehatan dan Kedokteran, Vol. 1(2), 62-69, 2020.
Leslie JL, Weddle E, Yum LK, Lin Y, Jenior ML, Ma JZ, et al. Cost‐effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa. 2020;1–12.
Damayanti H, Sajinadiyasa IGK, Risni HW, Sauriasari R et al. The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia. Kesmas National Public Health J. 2021;16(4):289–97.
ie Cui et al. Origin and Evolution of Pathogenic Coronavirus, ICAS key Laboratory of Special Pathogenic and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China. 2019.
Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol. 2020,1;886:173451.
